Interestingly, RBM17 knockdown inhibited AML cell growth (Supplementary Fig. 2b–d) and induced myeloid differentiation in the HL60 AML cell line (Supplementary Fig. 2e), the aforementioned OCI-AML-8227 cell line (Supplementary Fig. 2f), and primary AML cells (Fig. 2b, Supplementary Fig. 2g–i). Here, RBM17 is linked to acute myeloid leukemia.